Understand (SDD)

Complete chemical and biological sensor and overall modular mission payload (previously NBCRV SSU Capability Set 2.2) development and integration efforts of CRMMP LRIP assets. Continue sensor level developmental and operational testing and initiate system level developmental testing. Continue program office management and administration…

FY 2027 will facilitate the transition from WARP requirements to MACE requirements as WARP Increment 2. Increment 2 will continue the development of technologies in support of USSOCOM Theater requirements. Increment 2 will focus on additional personnel chemical exposure edge algorithms, expanding to include additional tactical radios…

Efforts support advanced experimentation activities with joint warfighters to identify chemical and biological (CB) defense capability gaps across the services. FY 2027 efforts integrates software capabilities developed under the CB WEARABLES program line with additional tactical, readiness, and performance monitoring functions…

Continue developing, prototyping, and maturing SO-P CB technologies to rapidly equip users with capabilities in response to new and emerging threats and opportunities. SPU RCDD develops multiple SO-P CB products that close rapid response gaps and reduce risk across the Enterprise through high risk / high reward advanced development…

Complete all developmental test and operational test (DT/OT) efforts, operational assessment, and Milestone C (MS C) Army Test and Evaluation Center evaluation report. Prepare documentation for phase four Low Rate Initial Production (LRIP) and MSC in 4Q FY 2027 with a LRIP contract award in 1Q FY 2028. Continue Program management and…

Initiate and award contract actions for maturation of multiple prototype systems, integrate prototypes into a holistic multi-modality approach. Conduct iterative prototyping with developmental test and evaluation on components/sub-components of remote sensing systems, to include CBRN Unmanned Aerial Systems (UAS). Support refinement of…

FY2027 planned work Continue Engineering Manufacturing Development activities with selected performer(s) to include analytical testing and clinical testing of prototype.

FY2026 to FY2027 change Increase due to ramp up of Engineering and Manufacturing Development Phase (EMD) activities after 4th quarter FY 2026 Milestone (MS) B decision.

FY2026 plans — current year Hold Milestone B decision to initiate Engineering and Manufacturing phase, and begin studies to verify assay performance for the selected performer(s).

Efforts support advanced experimentation activities with joint warfighters to identify CB defense capability gaps across the services. As part of a coordinated experimentation campaign, the program will use BA5 to verify, validate, and integrate physiological monitoring software capabilities into the hardware-focused decision support…

FY2027 planned work Continue development/expansion of well-characterized, traceable biological threat agent assays, reference materials and vital information for biological defense to known and emerging threats supporting fielded/developmental systems. Continue consolidating requirements across the enterprise to achieve economies of scale and continue to make these capabilities (assays, materials, and information) available through e-commerce and our threat agent database.

FY2026 to FY2027 change Minor change due to routine program adjustments.

FY2026 plans — current year Continue development/expansion of well-characterized, traceable biological threat agent assays, reference materials and vital information for biological defense to known and emerging threats supporting fielded/developmental systems. Continue consolidating requirements across the enterprise to achieve economies of scale and continue to make these capabilities (assays, materials, and information) available through e-commerce and our threat agent database.

FY2025 accomplishments Continued development/expansion of well-characterized, traceable biological threat agent assays, reference materials and vital information for biological defense to known and emerging threats supporting fielded/developmental systems. Continue consolidating requirements across the enterprise to achieve economies of scale and continue to make these capabilities (assays, materials, and information) available through e-commerce and our threat agent database.

FY2027 planned work FY 2027 BA5 funds will support the down select between up to two FFBS Increment 2 TMRR performers to move into the Engineering and Manufacturing Development (EMD) phase and initiates Developmental Testing / Operational Testing (DT/OT).

FY2026 to FY2027 change Program/project transitioned to Engineering and Manufacturing Development Phase. FY 2027 increase resources Increment 2 transition into Engineering and Manufacturing Development in FY 2027.

FY2027 planned work Food and Drug Administration (FDA) clearance of second and third panels, conduct remainder of Operational Tests for services.

FY2026 to FY2027 change Decrease aligns to planned conclusion of development effort and the start of product launch activities.

FY2026 plans — current year Obtain FDA clearance for first assay to support Milestone C, complete clinical trials for 2nd and 3rd assay, and conduct Operational Assessment.

FY2025 accomplishments Continued clinical trials needed for Food and Drug Administration (FDA) clearance of first two assays, completed pre-clinical trials of third assay, and started Developmental Testing (DT).

FY2027 planned work Conduct developmental testing and Initial Operational Test and Evaluation (IOT&E) for Increment II (Software Solutions I/II). Establish the initial laboratory reach back capability for Increment I to enable analysis of genetically engineered biological threats. Collaborate with advanced development partners to test objective agents within the program's requirement document. Expand development of protocols for sequencing additional complex sample types for NSIS Increment II.

FY2026 to FY2027 change Increase due to Increment II testing (both laboratory protocols and software), objective agent testing, development of protocols for sequencing additional complex sample types, and establishment of reach back laboratory capability for Increment I.

FY2026 plans — current year Complete NSIS Increment I testing to inform NSIS Increment I Milestone C/Full Rate Production decision in FY 2026. Develop protocols for complex sample types for NSIS Increment II.

FY2027 planned work Initiate AVCAD capability expansion to include Pharmaceutical Based Agents (PBA). Modify the contract to include algorithm development for the PBA, updating logistics products and support of verification testing. Continue program management, administrative processes and Other Government Agency (OGA) support for logistics and test support.

FY2026 to FY2027 change Decrease in FY 2027 funding due to the transition of the core product to production and deployment. Funding corelates to projected cost to incorporate Pharmaceutical Based Agent (PBA) capability.

FY2026 plans — current year Complete product development, and Systems Engineering. Complete program management and administrative processes and Other Government Agency (OGA) support for logistics and test evaluation results in support of a Full Rate Production (FRP) decision.

FY2025 accomplishments Continued product development, Systems Engineering, and completed multi-service operational test and evaluation (MOT&E). Continued program management and administrative processes and Other Government Agency (OGA) support for logistics and test evaluation results in support of a Full Rate Production (FRP) decision.

FY2027 planned work Complete operational testing requirements, to include First Article Test (FAT). Complete product verification testing due to vendor manufacturing optimization. Continue program management and support activities.

FY2026 to FY2027 change Funding decrease supports necessary scope required for first article test (FAT) and remaining product verification testing.

FY2026 plans — current year Complete developmental and operational test activities and complete operational assessment. Continue program management and support activities to focus on documentation and milestone activities to support Milestone C (MS C) and Full Rate Production (FRP) decision planned for 3Q FY 2026.

FY2025 accomplishments Initiated operational and developmental testing to include operational field test events and continued preparation for program Milestone events and program management activities.

FY2027 planned work Perform required testing in coordination with evaluator's to assess capability set one of Commercial Off-the-Shelf (COTS) systems to meet the requirements. Support program management and administration processes to include but not limited to program oversight, resource justification, budgeting and programming, milestone and schedule tracking.

FY2026 to FY2027 change Increase in FY 2027 to support Commercial Off-the-Shelf (COTS) Performance Testing scheduled activities.

FY2027 planned work Continue expansion of site locations for increased sequencing capabilities to monitor critical assay performance that detect biothreats, and exchange critical data (sequence information) collected at these sites. (One site per year). Continue expanding the repository of collected biothreat genomic information to a government access controlled, cloud-based information center to support analytics from the field. Continue expanding analytical tools and capabilities for evaluating assays and reagents. Continue expansion of biorepository of targeted biothreats and toxins.

FY2026 to FY2027 change Minor change due to routine program adjustments.

FY2026 plans — current year Continue expansion of site locations for increased sequencing capabilities to monitor critical assay performance that detect biothreats, and exchange critical data (sequence information) collected at these sites. (One site per year). Continue expanding the repository of collected biothreat genomic information to a government access controlled, cloud-based information center to support analytics from the field. Continue expanding analytical tools and capabilities for evaluating assays and reagents. Continue expansion of biorepository of targeted biothreats and toxins.

FY2025 accomplishments Continued expansion of site locations for increased sequencing capabilities to monitor critical assay performance that detect biothreats, and exchange critical data (sequence information) collected at these sites. (One site per year). Continue expanding the repository of collected biothreat genomic information to a government access controlled, cloud-based information center to support analytics from the field. Continue expanding analytical tools and capabilities for evaluating assays and reagents. Continue expansion of biorepository of targeted biothreats and toxins strategically against emerging diseases. Continue maintaining information storage capabilities on DoD Accredited sites.

FY2027 planned work Continue efforts to produce additional data to better assess detection, protection, and hazard mitigation capabilities against chemical, biological, toxic, and other threats. Conduct workshops on understanding advanced and emerging threat priorities to align with the CBDP. Conduct market surveys and assessments of technologies for rapid fielding by CBDP to mitigate current, advanced, or emerging threat gaps as needed.

FY2026 to FY2027 change Slight decrease due to reduced cost to testing on advanced technologies rather than on previously fielded systems and ongoing programs of record.

FY2026 plans — current year Continue efforts to address emerging chemical, biological, and other advanced threats. Maintain evaluation and assessment of ability to detect and mitigate threats. Update hazard data management tools to incorporate emerging threat information. Conduct market surveys and assessments of technologies for rapid fielding by the CBDP to mitigate emerging threat gaps as threats are identified. Conduct assessments of programs of record to understanding capabilities of fielded systems or systems to be fielded against advanced and emerging threats.

FY2025 accomplishments Continue efforts to produce additional data to better assess detection, protection, and hazard mitigation capabilities against chemical, biological, toxic, and other threats. Conduct workshops on understanding advanced and emerging threat priorities to align with the CBDP. Conduct market surveys and assessments of technologies for rapid fielding by CBDP to mitigate current, advanced, or emerging threat gaps as needed.

FY2026 to FY2027 change Program/project is entering completion and all activities will be closed. FY 2026 funded activities for completion of Capability Set (CS) 2.0 and CS 3.0 will continue testing activities as scheduled, to complete in FY 2027.

FY2026 plans — current year Complete deployment of chemical and radiological UAS payload and autonomous search and mapping, as part of Capability Set 2.0. Complete testing of standoff detection, cross platform teaming and upgrades to autonomous chemical and biological (CB) mapping in denied GPS operations for UASs, as part of Capability Set 3.0. Complete coordination of demonstrations and test events for additional services and end users. Complete program office management and administration process to include program oversight, resource justification, budgeting and programming, milestone, and schedule tracking.

FY2025 accomplishments Continued repackaging and integration of Standoff detection, cross platform teaming and upgrades to autonomous chemical and biological (CB) mapping in denied Global Positioning System (GPS) operations for UASs, at part of Capability Set 3.0. Initiated command and control integration, sensor integration for backpack portable UASs, and integration of preliminary biological identification on unmanned platforms at part of Capability Set 4.0. Continued coordination of demonstrations and test events for additional services and end users. Continued evaluation of capability to support service development of Concept of Operations (CONOPS).

FY2026 to FY2027 change Program/project transitioned to Production and Deployment Phase. Increment 1 has no FY 2027 BA5 planned due to transition into production and deployment phase.

FY2026 plans — current year Transition into the Production and Deployment phase. Complete Operational Testing (OT) and system verification review, and develop the product support package.

FY2025 accomplishments FFBS Increment 1 completed additional prototype engineering and testing to account for COTS sequencer hardware component product obsolescence. FFBS Increment 1 completed Engineering and Manufacturing Development (EMD) testing on prototypes and prepared for transition into the Production and Deployment phase. Finally, FFBS updated security classification modification, conducted lysis testing, and procured additional consumables to support additional early user demonstrations and evaluations.

FY2026 to FY2027 change Program/project funding transferred to another funding line. Funding and program efforts transition to CBRN Support to Command and Control (CSC2) under Project Understand/UN7 starting in FY 2027.

FY2026 plans — current year Begin transition of functions and features from MFK to CBRN Support to Command and Control (CSC2). Continue to deliver operational capability to the National Guard Bureau.

FY2025 accomplishments Continue engineering, development, and modernization of MFK in support of the time-phased transition of capabilities from MFK to CB Support to command and control.

FY2026 to FY2027 change Program/project funding transferred to another funding line. NBCRV SSU funding is transitioning to CBRN Reconnaissance Modular Mission Payload (CRMMP) in FY 2027 per the updated acquisition strategy.

FY2026 plans — current year Continue government strategic planning, systems engineering, logistics, training, test and evaluation, technical support, integration, and developmental testing. Continue chemical and biological sensor and integrated sensor suite prototype development and maturation of CBRN Reconnaissance Modular Mission Payload (CRMMP) (formerly Capability Set 2.2 (CS2.2)), and continue CRMMP developmental and operational testing.

FY2025 accomplishments Continued government strategic planning, systems engineering, logistics, training, technical support, integration, and test and evaluation. Initiated chemical and biological sensor and integrated sensor suite LRIP asset development, and initiate CS2.2 developmental testing.

FY2026 to FY2027 change Program/project transitioned to Production and Deployment Phase. FY 2027 decrease reflects Milestone C decision and transition to production and fielding activities.

FY2026 plans — current year Complete clinical trial and submit application for Food and Drug Administration (FDA) clearance to complete Engineering and Manufacturing Development (EMD), achieve Milestone C and award a production contract.

FY2025 accomplishments Started clinical trials and completed operational assessment.

FY2026 to FY2027 change FY 2027 changes reflect the shift from WARP prototype development to efforts towards multiple additional requirements from USSOCOM, specifically the additional incremental capability to Monitor for Acute CBRN Exposure (MACE).

FY2026 plans — current year Develop data sets and build algorithms for chemical and pharmaceutical-based agent exposure with the physiological monitoring device. Conduct testing to build data sets and inform algorithm development.

FY2025 accomplishments Completed integration of WARP prototypes to include interfacing with the Tactical Awareness Kit (TAK) Plug In. Completed development and testing of the hardened prototype.

FY2025 accomplishments Completed physical Military Standard (MIL-STD) and end-to-end (integration into USSOCOM equipment) test and evaluation activities. Completed multiple developmental and operational assessments.

FY2025 accomplishments Conducted Multi-Service Operational Test & Evaluation (MOT&E) and development test/operational test activities in preparation for Full Rate Production (FRP) decision.